title: Testosterone and prostate cancer: what are the risks for middle-aged men?
abstract: With increased recognition of the benefits of testosterone (T) therapy for middle-aged men, there has been a concomitant reexamination of the historical fear that raising T will result in more prostate cancer (PCa). Studies have failed to show increased risk of PCa in men with higher serum T, and supraphysiologic T fails to increase prostate volume or prostate-specific antigen in healthy men. This apparent paradox is explained by the Saturation Model, which posits a finite capacity of androgen to stimulate PCa growth. Modern studies indicate no increased risk of PCa among men with serum T in the therapeutic range.
authors.affiliation: Men's Health Boston, One Brookline Place, Suite 624, Brookline, MA 02445, USA. amorgent@bidmc.harvard.edu
authors.forename: Abraham
authors.initials: A
authors.lastname: Morgentaler
mesh_terms: D002986:Clinical Trials as Topic; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood* / Q000453:epidemiology; D012307:Risk Factors; D013739:Testosterone / Q000097:blood* / Q000172:deficiency / Q000627:therapeutic use*
chemical_list: D013739:Testosterone